223 related articles for article (PubMed ID: 32378285)
61. Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone.
Ye JH; Ho YF; On AW; Chen WW; Huang YM; Huang WI; Tang YW
Int J Clin Pharm; 2018 Aug; 40(4):911-920. PubMed ID: 30051228
[TBL] [Abstract][Full Text] [Related]
62. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study.
Coulter DM; Bate A; Meyboom RH; Lindquist M; Edwards IR
BMJ; 2001 May; 322(7296):1207-9. PubMed ID: 11358771
[TBL] [Abstract][Full Text] [Related]
63. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
[TBL] [Abstract][Full Text] [Related]
64. Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study.
Martin Arias LH; Martin Gonzalez A; Sanz Fadrique R; Salgueiro E; Sainz M
Int J Clin Pharm; 2018 Aug; 40(4):928-935. PubMed ID: 30066292
[TBL] [Abstract][Full Text] [Related]
65. Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study.
Hung GC; Liu HC; Yang SY; Pan CH; Liao YT; Chen CC; Kuo CJ
J Clin Psychiatry; 2016 Jan; 77(1):60-6. PubMed ID: 26613551
[TBL] [Abstract][Full Text] [Related]
66. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase.
Motola D; Donati M; Biagi C; Calamelli E; Cipriani F; Melis M; Monaco L; Vaccheri A; Ricci G
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1164-1171. PubMed ID: 28653802
[TBL] [Abstract][Full Text] [Related]
67. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
68. Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study.
Caldeira D; Rodrigues R; Abreu D; Anes AM; Rosa MM; Ferreira JJ
Expert Opin Drug Saf; 2018 Apr; 17(4):339-345. PubMed ID: 29463153
[TBL] [Abstract][Full Text] [Related]
69. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
Caster O; Aoki Y; Gattepaille LM; Grundmark B
Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
[TBL] [Abstract][Full Text] [Related]
70. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
Inácio P; Airaksinen M; Cavaco A
Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
[TBL] [Abstract][Full Text] [Related]
71. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
[TBL] [Abstract][Full Text] [Related]
72. Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies.
Koutkias VG; Lillo-Le Louët A; Jaulent MC
Expert Opin Drug Saf; 2017 Feb; 16(2):113-124. PubMed ID: 27813420
[TBL] [Abstract][Full Text] [Related]
73. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
[TBL] [Abstract][Full Text] [Related]
74. Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance).
Lertxundi U; Erezuma I; Hernandez R; Medrano J; Garcia M; Aguirre C
Int Clin Psychopharmacol; 2019 Mar; 34(2):89-92. PubMed ID: 30531551
[TBL] [Abstract][Full Text] [Related]
75. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
Gudin B; Ladhari C; Robin P; Laroche ML; Babai S; Hillaire-Buys D; Faillie JL
Therapie; 2020; 75(6):641-647. PubMed ID: 32418731
[TBL] [Abstract][Full Text] [Related]
76. Reporting of clozapine-induced gastrointestinal hypomotility and factors associated with fatal outcomes in Canada: A pharmacovigilance database study.
Liu CL; Maruf AA; Bousman CA
Psychiatry Res; 2020 Aug; 290():113048. PubMed ID: 32474068
[TBL] [Abstract][Full Text] [Related]
77. Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.
Cliff-Eribo KO; Choonara I; Dodoo A; Darko DM; Sammons H
Expert Opin Drug Saf; 2015; 14(12):1827-33. PubMed ID: 26436964
[TBL] [Abstract][Full Text] [Related]
78. Risk excess of mortality and use of antipsychotics: a case-noncase study.
Martín Arias LH; Treceño Lobato C; Pérez García S; Sáinz Gil M; Sanz Fadrique R; García Ortega P
Int Clin Psychopharmacol; 2017 Jan; 32(1):1-5. PubMed ID: 27602888
[TBL] [Abstract][Full Text] [Related]
79. Statin-induced myasthenia: A disproportionality analysis of the WHO's VigiBase pharmacovigilance database.
Gras-Champel V; Batteux B; Masmoudi K; Liabeuf S
Muscle Nerve; 2019 Oct; 60(4):382-386. PubMed ID: 31298743
[TBL] [Abstract][Full Text] [Related]
80. Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase
Kaguelidou F; Valtuille Z; Durrieu G; Delorme R; Peyre H; Treluyer JM; Montastruc F; Chouchana L
Drug Saf; 2023 Jan; 46(1):77-85. PubMed ID: 36459374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
